Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing novel, small molecule therapeutic drugs to address major unmet medical needs.
Locus' proprietary computational technology rapidly and accurately identifies the biologically relevant active binding site(s) of a protein and simultaneously designs de novo novel, small molecule antagonist or agonists of the protein's activity utilizing our proprietary fragment data set.
Locus Pharmaceuticals, Inc. is backed by a group of investors including Prism Venture Partners, Cooper Hill Partners, Amerindo Investment Advisors, Delphi Ventures, ING Furman Selz, Invesco Funds, Johnson & Johnson Development Corp., Liberty Wagner Asset Management, Life Science Venture Fund, Origin Capital and W Capital Partners.
For more information on Locus Pharmaceuticals, Inc., please visit their web site at www.locuspharma.com
Locus' proprietary computational technology rapidly and accurately identifies the biologically relevant active binding site(s) of a protein and simultaneously designs de novo novel, small molecule antagonist or agonists of the protein's activity utilizing our proprietary fragment data set.
Locus Pharmaceuticals, Inc. is backed by a group of investors including Prism Venture Partners, Cooper Hill Partners, Amerindo Investment Advisors, Delphi Ventures, ING Furman Selz, Invesco Funds, Johnson & Johnson Development Corp., Liberty Wagner Asset Management, Life Science Venture Fund, Origin Capital and W Capital Partners.
For more information on Locus Pharmaceuticals, Inc., please visit their web site at www.locuspharma.com
Investors 1
| Date | Name | Website |
| - | ATEL Capit... | atel.com |
Mentions in press and media 4
| Date | Title | Description |
| 11.10.2011 | Azelon secures $4.5 million in Series A funding, restructures company | The financing has prompted a restructuring of the company, formerly called Zelos Therapeutics. Don Hayden has been appointed executive chairman and Joan Lau has been named president and CEO. Lau succeeds Brian MacDonald, who will remain wit... |
| 09.07.2010 | Ansaris grabs $1.7M for oncology, immunology drug development | The funding was sourced from Ansaris’ existing investors, which include Prism Venture Partners, HBM BioVentures Ltd., and SR One, the venture arm of GlaxoSmithKline. “It shows our investors’ confidence in what we’re doing now,” Lau said, th... |
| - | Azelon secures $4.5 million in Series A funding, restructures company | Azelon Pharmaceuticals in West Conshohocken, Pennsylvania, has received $4.5 million in Series A financing from three venture capital firms to develop its nasal spray formulation of teriparatide for the treatment of osteoporosis. Palo Alto,... |
| - | Ansaris grabs $1.7M for oncology, immunology drug development | Drug discovery firm Ansaris has received a $1.7 million investment to further development of therapeutics with oncology, immunology and inflammatory targets, according to a regulatory filing. The filing was made under the name of Ansaris’ p... |